Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
Harrow Health, Inc. (HROW)
Last harrow health, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The US$1.8b market-cap company posted a loss in its most recent financial year of US$17m and a latest trailing-twelve-month loss of US$5.0m shrinking the gap between loss and breakeven. The most pressing concern for investors is Harrow's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Consensus from 8 of the American Pharmaceuticals analysts is that Harrow is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of US$56m in 2026. The company is therefore projected to breakeven around 12 months from now or less. We calculated the rate at whic
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow Health, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]Seeking Alpha
- Harrow to Present at Two Investor Conferences in DecemberGlobeNewswire
- Harrow Announces Closing of Acquisition of Melt PharmaceuticalsGlobeNewswire
- Harrow (NASDAQ:HROW) had its price target raised by analysts at LADENBURG THALM/SH SH from $64.00 to $66.00. They now have a "buy" rating on the stock.MarketBeat
HROW
Earnings
- 11/10/25 - Beat
HROW
Sec Filings
- 1/8/26 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- HROW's page on the SEC website